| P50 | author | Shirin Kalimuddin | Q97642409 |
| | David C. Lye | Q42216661 |
| P2093 | author name string | Thuan Tong Tan | |
| | Jenny G H Low | |
| | Rachel Phillips | |
| | Sophia Archuleta | |
| | Siew Pei Ong | |
| | Yvonne F Z Chan | |
| P2860 | cites work | Methicillin-resistant Staphylococcus aureus therapy: past, present, and future | Q27011165 |
| | Vancomycin and the red-man syndrome: pharmacodynamics of histamine release | Q28338684 |
| | Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? | Q33617737 |
| | Vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations: study protocol for a phase IIB randomized controlled trial | Q33844670 |
| | Pragmatic Trials. | Q54484116 |
| | Prospective evaluation of red man syndrome in patients receiving vancomycin | Q72888295 |
| | Infective endocarditis: changing epidemiology and predictors of 6-month mortality: a prospective cohort study | Q79421831 |
| | Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study | Q82644438 |
| | Clinical characteristics of vancomycin minimum inhibitory concentration of 2 μg/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia | Q84563829 |
| | Influence of early daptomycin therapy on treatment outcome of meticillin-resistant Staphylococcus aureus bacteraemia with high vancomycin minimum inhibitory concentrations | Q85891650 |
| | Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study | Q86222628 |
| | Randomized phase II clinical trials | Q93658163 |
| | Infectious diseases consultation lowers mortality from Staphylococcus aureus bacteremia | Q33895690 |
| | Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis | Q33898620 |
| | In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers | Q33982424 |
| | Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children | Q34157657 |
| | Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus | Q34558111 |
| | Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 |
| | Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis | Q35030135 |
| | Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers | Q35091557 |
| | Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens | Q35701450 |
| | An association between bacterial genotype combined with a high-vancomycin minimum inhibitory concentration and risk of endocarditis in methicillin-resistant Staphylococcus aureus bloodstream infection | Q35745676 |
| | Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia | Q35879117 |
| | Pneumonia caused by methicillin-resistant Staphylococcus aureus | Q37156705 |
| | Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections | Q37287739 |
| | Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. | Q37392917 |
| | Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program | Q37509110 |
| | Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists | Q37537565 |
| | Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists | Q37623755 |
| | Adaptive clinical trials in oncology | Q37953783 |
| | The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. | Q37981103 |
| | Efficiencies of platform clinical trials: A vision of the future | Q38904226 |
| | Vancomycin MIC creep in methicillin-resistant Staphylococcus aureus (MRSA) isolates from 2006 to 2010 in a hospital in China | Q41084998 |
| | Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin | Q43143854 |
| | Infectious diseases consultation and the management of Staphylococcus aureus bacteremia | Q44044205 |
| | The platform trial: an efficient strategy for evaluating multiple treatments. | Q45982371 |
| | Red man syndrome: incidence, etiology, and prophylaxis. | Q46032651 |
| | Are there differences in hospital cost between patients with nosocomial methicillin-resistant Staphylococcus aureus bloodstream infection and those with methicillin-susceptible S. aureus bloodstream infection? | Q46062559 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P921 | main subject | Staphylococcus aureus | Q188121 |
| | vancomycin | Q424027 |
| P304 | page(s) | 305 | |
| P577 | publication date | 2018-06-01 | |
| P1433 | published in | Trials | Q7840023 |
| P1476 | title | A randomized phase 2B trial of vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations - results of a prematurely terminated study | |
| P478 | volume | 19 | |